PATENT CLAIM ANALYSIS

Application Number: 15769308
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "339000"]

Abstract:
The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.

Claim (Index 23):
The method according to  claim 21 , comprising measuring the expression levels of at least one, at least two, at least three, at least four or all of the forty signature genes consisting of BAX, C1QBP, FDXR, GAMT, RPS27L, SLC25A11, TP53, TRIAP1, ZMAT3, AEN, C12orf5, GRSF1, EIF2D, MPDU1, STX8, TSFM, DISC1, SPCS1, PRPF8, RCBTB1, SPAG7, TIMM22, TNFRSF10B, ACADSB, DDB2, FAS, GDF15, GREB1, PDE12, POLH, C19orf60, HHAT, ISCU, MDM2, MED31, METRN, PHLDA3, CDKN1A, SESN1 and XPC.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12438944', '13950881', '14560519', '14430635', '15566336']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7375005021452953
- 35 USC 102 Novelty (BERT): 0.5681433434067296
- Combined Prediction Score: 0.7205647862714387
- Mean Citation Score: 388.860316
- Max Citation Score: 521.67804
- Similarity Product: 306.4888211279154

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test